ZyVersa Therapeutics Inc. (ZVSA)
0.73
0.02 (3.11%)
At close: Apr 24, 2025, 12:21 PM
Company Description
ZyVersa Therapeutics, Inc., a clinical stage biopharmaceutical company, develops and commercializes products for the treatment of renal and inflammatory diseases.
It engages in the development of VAR 200, a cholesterol efflux mediator to treat focal segmental glomerulosclerosis, alport syndrome, and diabetic kidney disease; and IC 100, a novel inflammasome ASC inhibitor for treatment of multitude of inflammatory diseases.
ZyVersa Therapeutics, Inc. is headquartered in Weston, Florida.
ZyVersa Therapeutics Inc.

Country | United States |
IPO Date | Feb 11, 2022 |
Industry | Biotechnology |
Sector | Healthcare |
Employees | 7 |
CEO | Stephen C. Glover |
Contact Details
Address: 2200 N. Commerce Parkway Weston, Florida United States | |
Website | https://www.zyversa.com |
Stock Details
Ticker Symbol | ZVSA |
Exchange | NASDAQ |
Fiscal Year | January - December |
Reporting Currency | USD |
CIK Code | 0001859007 |
CUSIP Number | 98987D201 |
ISIN Number | US98987D2018 |
Employer ID | 86-2685744 |
SIC Code | 2834 |
Key Executives
Name | Position |
---|---|
Stephen C. Glover | Co-Founder, Chairman, Chief Executive Officer & President |
Peter Wolfe | Chief Financial Officer & Secretary |
Dr. Pablo A. Guzman FACC, M.D. | Chief Medical Officer, Senior Vice President of Medical Affairs & Chairman of Renal Scientific Advisory Board |
Latest SEC Filings
Date | Type | Title |
---|---|---|
Apr 17, 2025 | ARS | Filing |
Apr 17, 2025 | DEFA14A | Filing |
Apr 17, 2025 | DEF 14A | Filing |
Apr 07, 2025 | PRE 14A | Filing |
Apr 07, 2025 | 8-K | Current Report |
Apr 04, 2025 | S-3 | Filing |
Mar 27, 2025 | 10-K | Annual Report |
Mar 07, 2025 | 8-K | Current Report |
Jan 24, 2025 | S-8 | Filing |
Jan 17, 2025 | DEF 14A | Filing |